Microvascular Therapeutics

📍 Tucson, United States🗓 Founded 2009👥 9 employees💰 Last funded Nov 2022
Biotechnology Research🌐 mvtpharma.com
Website LinkedIn
Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world’s #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2009
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Microvascular Therapeutics?
Microvascular Therapeutics has 1 investors on record on gritt.io.
When did Microvascular Therapeutics last raise funding?
The most recent investment in Microvascular Therapeutics recorded on gritt.io was in November 2022.
When was Microvascular Therapeutics founded?
Microvascular Therapeutics was founded in 2009.
What industry is Microvascular Therapeutics in?
Microvascular Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Microvascular Therapeutics based?
Microvascular Therapeutics is headquartered in Tucson, United States.